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ABSTRACT
Background    Nutritional status is strongly associated 
with prognosis in cancer patients. Controlling Nutritional 
Status (CONUT) score is a nutritional marker based on 
serum albumin, cholesterol, and total lymphocyte count. 
We investigated the prognostic significance of a combi-
nation of the tumor marker carcinoembryonic antigen 
(CEA) and CONUT score (T-CONUT) in colorectal 
cancer (CRC) patients. 
Methods    A total of 522 patients who underwent 
surgery for CRC at our hospital were retrospectively 
enrolled in this study. 
Results    Patients were divided into groups based on the 
results of receiver operating characteristic (ROC) curve 
analysis as follows: CONUThigh (CONUT score ≥ 3) and 
CONUTlow (CONUT score < 3), and CEAlow (< 5 ng/mL) 
and CEAhigh (≥ 5 ng/mL). The 5-year overall survival 
(OS) rates of patients in the CONUTlow and CONUThigh 
groups were 76.0% and 53.9%, respectively (P < 0.0001), 
and in the CEAlow and CEAhigh groups were 80.7% and 
47.6%, respectively (P < 0.0001). Regarding T-CONUT, 
the 5-year OS rates of patients with CEAlow/CONUTlow, 
CEAlow/CONUThigh, CEAhigh/CONUTlow, and CEAhigh/
CONUThigh were 84.7%, 69%, 55.3%, and 36.1%, re-
spectively (P < 0.0001). Multivariate analysis identified 
T-CONUT score as an independent prognostic indicator 
in CRC patients.
Conclusion    T-CONUT may be a useful tool for pre-
dicting prognosis in CRC patients.
Key words    carcinoembryonic antigen; colorectal can-
cer; Controlling Nutritional Status score; prognosis
Recent advances in surgical techniques, perioperative 
management, and chemotherapy, including the use of 
molecular targeting drugs, have improved the prog-
nosis of colorectal cancer (CRC) patients; however, it 
still ranks fourth with respect to cancer-related deaths 
worldwide.1 Although colectomy with regional lymph 
node dissection is the main curative treatment for CRC, 
many patients experience recurrence even after complete 
removal of the tumor (R0 resection). Recent progress in 
chemotherapy has improved the prognosis of unresect-
able advanced and recurrent CRC,2 while early detection 
of recurrence has been shown to increase survival after 
curative colectomy for CRC.3–4 It is therefore important 
to determine the factors affecting postoperative prog-
nosis in patients with CRC. To this end, serum tumor 
markers (TMs) are easy to measure and potentially 
useful for diagnosis, predicting survival rates, and mon-
itoring recurrence following surgery. Carcinoembryonic 
antigen (CEA) and carbohydrate antigen (CA) 19-9 are 
the most commonly used TMs for diagnosis, treatment 
monitoring, and predicting the prognosis in patients with 
CRC.5 
 Recent studies demonstrated that the prognoses of 
various types of cancers were also affected by patient-
related factors, including inflammation, immunocom-
petence, and nutrition, with the correlation between 
nutritional status and cancer prognosis being of partic-
ular interest. Nutritional status has been shown to be an 
important risk factor associated with postoperative mor-
bidity and mortality,6–8 and various tools for assessing 
nutritional status have been reported.9–11 Furthermore, 
recent studies also demonstrated a close association 
between nutritional status and prognosis in cancer pa-
tients, including patients with CRC.12–14 The Controlling 
Nutritional Status (CONUT) score, which includes mea-
sures of serum albumin, total cholesterol, and peripheral 
lymphocyte count, was recently reported as a new tool 
for evaluating nutritional status.15 The CONUT score has 
been reported to be closely associated with prognosis in 
gastric cancer, esophageal cancer, and CRC.16–18 Serum 
TMs in CRC patients are mainly derived from the can-
cer itself, while the CONUT score reflects the patient’s 
nutritional status, and both approaches have been shown 
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to be useful in predicting the prognosis of CRC patients. 
The different origins of TMs and CONUT score sug-
gested that their combination might be superior to either 
TMs or CONUT score alone for predicting the prog-
nosis of CRC patients. The current study thus aimed to 
evaluate the prognostic significance of the combination 
of serum TMs and CONUT score in patients with CRC.
MATERIALS AND METHODS
Patients 
This retrospective study enrolled 522 stage I – IV CRC 
patients who underwent colorectal resection at our hospi-
tal between January 2007 and December 2015. The clin-
icopathologic findings were assessed according to the 
8th edition of the Japanese Classification of Colorectal 
Carcinoma.19 Patients were checked periodically for 
early recurrence by diagnostic imaging (chest X-ray, 
colonoscopy, ultrasonography, and computed tomogra-
phy). Causes of death and patterns of recurrence were 
determined by reviewing medical records, including 
laboratory data, ultrasonography, computed tomography, 
scintigrams, and laparotomies, or by direct inquiry with 
family members. We collected data on preoperative 
blood tests within one month before surgery, including 
serum albumin, total cholesterol, and total peripheral 
blood lymphocyte count (TLC) from the patients’ 
records. This study was approved by the Institutional 
Review Board of Tottori University (Approved number: 
17A105).
CONUT score
CONUT score was calculated based on serum albumin, 
total cholesterol, and TLC (Table 1). These factors were 
scored according to cut-off values, and the sum of the 
scores was used as the CONUT score. The patients were 
then divided into four categories according to CONUT 
Table 1. Controlling Nutritional Status (CONUT) scor-
ing system
Parameters
Serum albumin 
(g/dL) ≥ 3.5 3.0–3.49 2.5–2.9 < 2.5
Score 1 2 4 6
Total lymphocyte 
count (/mm3)  ≥ 1600 1200–1599 800–1199 < 800
Score 0 1 2 3
Total cholesterol 
(mg/dL)  ≥ 180 140–180 100–139 < 100
Score 0 1 2 3
CONUT score 0–1 2–4 5–8 9–12
Assessment Normal Light Moderate Severe
Table 2. Relationships between Controlling Nutrition-
al Status (CONUT) score and clinicopathological vari-
ables in patients with colorectal cancer
Variable CONUTlow CONUThigh P value
(n = 364) (n = 158)
Age (years) 0.013
< 70 197 57
≥ 70 217 101
Gender 0.86
Male 202 89
Female 162 69
Tumor size (cm) < 0.0001
< 4 215 58
≥ 4 149 100
Tumor location 0.024
Colon 218 111
Rectum 146 47
Histology* 0.019
Differentiated 337 136
Undifferentiated 27 22
Depth of invasion† < 0.0001
T1 / 2 143 27
T3 / 4 221 131
Lymph node metastasis 0.44
Absent 222 102
Present 142 56
Distant metastasis 0.0038
Absent 323 125
Present 41 33
Lymphatic invasion‡ 0.46
Ly 0 / 1 204 83
Ly 2 / 3 160 75
Vascular invasion§ 0.3
V 0 / 1 245 99
V 2 / 3 119 59
Curability|| 0.005
A/B 330 129
C 34 29
*Differentiated, papillary or tubular adenocarcinoma; undiffer-
entiated, poorly differentiated or mucinous adenocarcinoma, or 
signet-ring cell carcinoma
†T1, tumor invasion of the lamina propria or submucosa; T2, tu-
mor invasion of the muscularis propria; T3, tumor invasion of the 
subserosa or within adventitia; T4, tumor penetration of the serosa 
or tumor invasion of adjacent organs
‡Ly0–Ly3, grade of lymphatic invasion
§V0–V1, grade of vascular invasion
||Curability, A, R0 in Stage0, I, II, or III; B, R0 in Stage IV or R1 
in any Stage; C, R2 in any Stage
score as follows: normal (score 0–1), light (score 2–4), 
moderate (score 5–8), and severe (score 9–12).
Statistical analysis
Individual variables were compared among groups using 
χ2 tests. Receiver operating characteristic (ROC) curves 
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Fig. 1. Overall survival curves for colorectal patients according to CONUT score (a) and serum CEA level (b). CEA, carcinoembryonic 
antigen; CONUT, Controlling Nutritional Status.
Fig. 2. Overall survival curves (a) and disease-specifi c survival curves (b) for colorectal cancer patients according to the combination of 
CONUT score and serum CEA level. CEA, carcinoembryonic antigen; CONUT, Controlling Nutritional Status.
were generated and the area under the curve (AUC) 
was determined for survival analysis and to identify the 
optimal cut-off value for the CONUT score. Survival 
curves were calculated according to the Kaplan–Meier 
method. Differences between the curves were examined 
by log-rank tests. Possible prognostic factors for overall 
survival (OS) were subjected to multivariate analysis 
using a Cox’s proportional hazards model and stepwise 
analysis. The covariates included in the analysis were 
age, gender, tumor size, histology, tumor location, depth 
of invasion, lymph node metastasis, distant metastasis, 
lymphatic invasion, vascular invasion, and T-CONUT. 
The accepted level of significance was P < 0.05. All 
statistical analyses were performed using SPSS software 
(SPSS for Windows Version 24, SPSS Inc., Chicago, IL). 
Fig. 3. Cause of death of colorectal cancer patients according to 
the combination of CONUT score and serum CEA level. CEA, 
carcinoembryonic antigen; CONUT, Controlling Nutritional 
Status.
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RESULTS
There were 271, 149, 68, and four patients with normal, 
light, moderate, and severe CONUT scores, respec-
tively. According to ROC analysis, the optimal cut-off 
CONUT score for OS was 3 (AUC = 0.627, P < 0.0001). 
Based on these results, the patients were divided into 
two groups as follows: CONUThigh (CONUT score ≥ 3; 
n = 158) and CONUTlow (CONUT score < 3; n = 364). 
The relationships between CONUT score and clinico-
pathologic factors are shown in Table 2. CONUThigh was 
more common in elderly patients and in patients with 
large tumors, rectal cancer, and undifferentiated tumors, 
compared with non-elderly patients and patients with 
small tumors, colon cancer, and differentiated tumors, 
respectively. Furthermore, CONUThigh was also more 
frequent in patients with T3/T4 tumors, those with dis-
tant metastasis, those with Curability C compared with 
patients with T1/T2 tumors, those without distant metas-
tasis, and those with Curability A and B. One hundred 
and fifty patients died during the follow up period, 80 
patients died from CRC progression or recurrence, and 
70 patients died from other causes, such as other cancers 
(n = 17), pneumonia (n = 4), stroke (n = 3), myocardial 
infarction (n = 1), and other remaining unknown causes. 
There were no surgically related deaths. The 5-year OS 
rate was significantly higher in patients in the CONUTlow 
(76%) compared with the CONUThigh (53.9%) group (P < 
0.0001) (Fig. 1a). 
 The mean serum CEA level was 16.2 ng/mL (range: 
0.1–1166 ng/mL). The patients were also divided into 
two groups according to serum CEA concentration as 
follows: CEAhigh (≥ 5 ng/mL; n = 177) and CEAlow (< 5 
ng/mL; n = 345). The 5-year OS rate was significantly 
higher in patients in the CEAlow (80.7%) compared with 
the CEAhigh (47.6%) group (P < 0.0001) (Fig. 1b). 
 We determined the prognostic significance of 
the combination of CONUT score and CEA level 
(T-CONUT) by dividing the patients into four groups 
as follows: CEAlow/CONUTlow (n = 257); CEAlow/
CONUThigh (n = 88); CEAhigh/CONUTlow (n = 107); and 
CEAhigh/CONUThigh (n = 70). Survival status was deter-
mined by ROC curves and the discriminatory abilities of 
CEA, CONUT, and T-CONUT were compared based on 
the AUCs. The AUCs of CEA, CONUT, and T-CONUT 
for OS were 0.66 (P < 0.0001), 0.627 (P < 0.0001), and 
0.71 (P < 0.0001), respectively, indicating that T-CONUT 
was more useful than either indicator alone for predict-
ing OS in CRC patients. The 5-year OS rates of patients 
with CEAlow/CONUTlow, CEAlow/CONUThigh, CEAhigh/
CONUTlow, and CEAhigh/CONUThigh were 84.7%, 69%, 
55.3%, and 36.1%, respectively (P < 0.0001) (Fig. 2a). 
Moreover, the equivalent 5-year disease-specific survival 
rates were 92.9%, 82.1%, 68.8%, and 54.5%, respectively 
(P < 0.0001) (Fig. 2b). We then examined the signifi-
cance of T-CONUT for survival rate by Kaplan-Meier 
curve in stage I – IV. In stage I and IV CRC patients, 
there was no significant difference for survival rate 
among each T-CONUT group; however, in stage II and 
III patients, significant difference was observed for sur-
vival among each T-CONUT group similar to all stages 
(stage II: P = 0.001, and stage III: P = 0.006).
 Regarding the cause of death, cancer-related deaths 
were observed in 14 (5.4%), 13 (14.8%), 26 (24.3%), 
and 27 patients (38.6%) in the CEAlow/CONUTlow, 
CEAlow/CONUThigh, CEAhigh/CONUTlow, and CEAhigh/
CONUThigh groups, respectively (P < 0.0001) (Fig. 3), 
while deaths due to other causes were observed in 23 
(8.9%), 15 (17%), 16 (15%), and 16 patients (22.9%), 
respectively (P = 0.01) (Fig. 3).
 We then demonstrated ROC analysis of CEA, 
CONUT, and T-CONUT for cancer-related death and 
death from other cause, respectively. The AUCs of 
CEA, CONUT, and T-CONUT for cancer-related death 
were 0.762, 0.619, and 0.736, respectively, and while 
Table 3. Multivariate analyses of prognostic factors for overall survival in patients with colorectal cancer
P value Hazard ratio 95% CI
Age* < 0.0001 1.049 1.030–1.069
Lymph node metastasis (N0–N3)† 0.0007 1.385 1.148–1.672
Distant metastasis (absent or present) < 0.001 3.273 2.189–4.893
T-CONUT < 0.0001
CEALow and CONUTLow vs. CEAHigh and CONUTHigh < 0.0001 0.328 0.202–0.531
CEALow and CONUTHigh vs. CEAHigh and CONUTHigh 0.15 0.693 0.42–1.144
CEAHigh and CONUTLow vs. CEAHigh and CONUTHigh 0.21 0.752 0.482–1.174
*Continuous variable
†N0, no regional lymph node metastasis; N1, metastasis in 1–3 pericolic, perirectal, or intermediate lymph nodes; N2, metastasis in ≥ 4 
pericolic, perirectal, or intermediate lymph nodes; N3, metastasis in main lymph nodes or lateral lymph nodes
CEA, carcinoembryonic antigen; CI, confidence interval; CONUT, Controlling Nutritional Status.
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CEA had the highest AUC among these prognostic 
factors. Furthermore, the AUCs of CEA, CONUT, and 
T-CONUT for death from other causes were 0.589, 0.563, 
and 0.606, respectively, and T-CONUT was the highest 
AUC among them.
 Multivariate analysis identified T-CONUT score as 
an independent prognostic indicator in CRC patients, 
together with age, lymph node metastasis, and distant 
metastasis (Table 3). 
DISCUSSION
The results of the current study demonstrated that 
CONUT score was useful for predicting the prognosis 
of CRC patients. Our results were similar to previous 
reports that demonstrated the significance of CONUT 
score for the patients after surgery with several can-
cers.16–18 Previous study also demonstrated that CONUT 
score was useful prognostic indicator in metastatic col-
orectal cancer patients receiving first line chemothera-
py.20 CONUT includes measures of serum albumin, total 
cholesterol, and TLC. Albumin, which is the most abun-
dant blood plasma protein, is produced in the liver and 
forms a large proportion of all plasma protein. Serum 
albumin is the standard factor used to assess a patient’s 
nutritional status and has been reported to be closely as-
sociated with the prognosis of various cancers, including 
CRC.21–23 TLC is also thought to reflect nutritional sta-
tus, as well as being an indicator of immunocompetence. 
Lymphocytes include CD4+ and CD8+ T cells, natural 
killer (NK) cells, NK T cells, gamma-delta T cells, and 
B cells, which are reported to be closely associated with 
tumor immunity. Decreased numbers of these cells are 
thus likely to be associated with impaired tumor im-
munity, resulting in tumor progression. Several studies 
have demonstrated associations between the numbers 
of tumor-infiltrating lymphocytes, including CD4+ and 
CD8+ T cells, and cancer prognosis.24–26 Furthermore, 
decreased numbers of immune cells, including NK cells, 
B cells, and gamma-delta T cells, in peripheral blood 
and cancer tissue have been correlated with poor prog-
nosis in various cancers.27–29 TLC might thus be a good 
indicator of cell-mediated immune status, including both 
acquired and adaptive immunities, as well as humoral 
immune status against CRC, indicating that the CONUT 
score reflects not only an individual’s nutritional status, 
but also their immune status. 
 Both serum albumin level and TLC are included in 
the prognostic nutritional index (PNI), which is one of the 
most frequently used indicators for evaluating nutritional 
status. PNI was recently shown to be closely associated 
with the prognosis of various types of cancer,13–14, 30 indi-
cating the values of both nutritional and immune status 
as prognostic indicators in cancer patients. In addition 
to serum albumin and TLC, the CONUT score also 
includes a measure of serum cholesterol, which has been 
reported to correlate with tumor progression and patient 
survival in various cancers, including CRC.31–33 
 We also demonstrated that serum CEA level was 
closely associated with the prognosis of CRC patients in 
this study. Notably, however, CONUT score was useful 
for predicting the prognosis of CRC patients regardless 
of serum CEA level. Serum CEA mainly reflects the 
tumor status, whereas CONUT score reflects the pa-
tient’s overall condition, including their nutritional and 
immune statuses. These results suggest that the combi-
nation of these two factors (T-CONUT) might provide 
more accurate prognostic information for CRC patients 
than either factor alone, as demonstrated by the current 
ROC analysis. Furthermore, T-CONUT was a more 
useful prognostic factor in patients with stage II or III 
CRC; therefore, considering the indication of adjuvant 
chemotherapy, T-CONUT may be helpful in usual clin-
ical practice. Moreover, T-CONUT was also identified 
as an independent prognostic indicator by multivariate 
analysis. 
 Regarding cause of death, T-CONUT was related 
to both cancer-related deaths and deaths due to other 
causes; however, it was more closely related to other 
causes of death. Migita et al. previously used PNI to 
evaluate the preoperative immunonutritional status of 
patients and found that low PNI scores were associated 
with a higher risk of non-cancer deaths.34 A similar 
study showed that low PNI scores increased the chance 
of respiratory failure due to pneumonia in older pa-
tients with gastric cancer, compared with patients with 
high PNI scores.35 Overall, these findings suggest that 
poor nutritional status increases the risk of death from 
non-cancer-related diseases after surgery. This indicates 
the benefit of using patient-related factors for predicting 
the prognosis of cancer patients.
 Our study had some limitations. First it was a retro-
spective study and was therefore subject to bias. Second, 
we divided patients into two groups with high and low 
CONUT scores using a cut-off value of 3; however, 
cut-off values for CONUT scores have varied among 
reports, and the optimal cut-off value remains unclear. 
Third, the number of patients included in the current 
study was small, and further large-scale, prospective, 
randomized, controlled trials are needed to confirm the 
results.
 In conclusion, T-CONUT may be a useful prog-
nostic indicator in patients with CRC. Given that serum 
markers can be measured quickly, easily, and non-
invasively, T-CONUT may represent a useful biological 
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marker in routine clinical settings. 
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